CyFlow CD79a PE
| 品番 | CU479884 | ||
|---|---|---|---|
| 抗体名 | Anti-H/M/R CD79A PE,HM47 | ||
| 包装単位 | 100 tests | ||
| 濃度 | - | ||
| 容量 | 1 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG1 PE (BV655324) |
||
| 反応性|交差吸着 | Human | Mouse | Rat | Non-Human Primates | Pig | Cow | Horse | Dog | Rabbit | Guinea pig | Chicken | レーザー | Blue, Green, Yellow |
| 抗原 | CD79a, IgA, MB-1, MB1 | 最大蛍光波長 | 576 nm |
| クローン | HM47 | 最大励起波長 | 496 nm, 565 nm |
| ホスト | Mouse | 標識/Format | PE |
| アイソタイプ | IgG1 | 研究分野 | Immunophenotyping |
| クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-H/M/R CD79A PE,HM47
特異性
The mouse monoclonal antibody HM57 recognizes CD79a, a 40-45 kDa subunit of B cell antigen-specific receptor (BCR) and its early developmental forms.
抗原情報
CD79a (Ig α, MB1) forms disulfide-linked heterodimer with CD79b (Ig β, B29). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with λ5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. At the plasma cell stage, CD79a is present as an intracellular component. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Bhargava P, Kallakury BV, Ross JS, Azumi N, Bagg A: CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone‑dependent manner. Am·J·Clin·Pathol. 2007·Aug; 128(2):306‑13. <·PMID:·17638667·>
• Fernandez NJ, West KH, Jackson ML, Kidney BA: Immunohistochemical and histochemical stains for differentiating canine cutaneous round cell tumors.. Vet·Pathol. 2005·Jul; 42(4):437‑45. <·PMID:·16006603·>
• Islas-Ohlmayer M, Padgett-Thomas A, Domiati-Saad R, Melkus MW, Cravens PD, Martin Mdel P, Netto G, Garcia JV: Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein‑Barr virus. J·Virol. 2004·Dec; 78(24):13891‑900. <·PMID:·15564497·>
• Mason DY, Cordell JL, Tse AG, van Dongen JJ, van Noesel CJ, Micklem K, Pulford KA, Valensi F, Comans-Bitter WM, Borst J, et al: The IgM‑associated protein mb‑1 as a marker of normal and neoplastic B cells. J·Immunol. 1991·Dec·1; 147(11):2474‑82. <·PMID:·1747162·>
• Rassenti LZ, Kipps TJ: Expression of Ig‑beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy‑chain allelic exclusion. Blood. 2000·Apr·15; 95(8):2725‑7. <·PMID:·10753858·>
• Torlakovic E, Torlakovic G: B‑cell markers in lymphocyte predominance Hodgkin disease. Arch·Pathol·Lab·Med. 2002·Jul; 126(7):862‑3. <·PMID:·12123231·>
• Zhao XF, Hassan A, Perry A, Ning Y, Stass SA, Dehner LP: C‑MYC rearrangements are frequent in aggressive mature B‑Cell lymphoma with atypical morphology. Int·J·Clin·Exp·Pathol. 2008·Jan·1; 1(1):65‑74. <·PMID:·18784824·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN